Plus   Neg

Stock Alert: Horizon Therapeutics Jumps 15% On Quarterly Results

Shares of Horizon Therapeutics Public Ltd. Co. (HZNP) are gaining over 15% on Wednesday morning after the company's second-quarter results trumped Wall Street view, driven by "tremendous" response for its drug Tepezza, a treatment for Thyroid Eye Disease. The company also lifted its full-year revenue outlook.

HZNP is currently trading at $71.12, up $9.33 or 15.10%, on the Nasdaq.

Second-quarter net loss was $80.0 million or $0.42 per share, wider than last year's loss of $5.1 million or $0.03 per share. Adjusted earnings were $0.40 per share, lower than last year's earnings of $0.49 per share. Analysts' had a consensus earnings estimate of $0.36 per share.

Revenues for the quarter rose 44% to $462.8 million from $320.6 million last year. Analysts expected revenues of $332.45 million.

"Driving our record second-quarter performance was the continued tremendous patient and physician response to Tepezza, along with our outstanding commercial execution, making the Tepezza launch one of the most successful rare disease medicine launches ever, despite a challenging COVID-19 environment," said CEO Tim Walbert.

Looking forward, the company now expects full-year 2020 net sales between $1.85 billion to $1.90 billion, an increase from the previous guidance range of $1.40 billion to $1.45 billion. Horizon now expects Tepezza full-year 2020 net sales of greater than $650 million, compared to the previous guidance of greater than $200 million. Analysts currently estimate sales of $1.54 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) has gone ahead with the approval of antiviral drug remdesivir as first treatment for COVID-19, notwithstanding last week's findings by the World Health Organization (WHO) that the drug is not effective for COVID-19 treatment. Thursday, Gilead Sciences announced that the FDA approved remdesivir, sold under the brand name Veklury. Integrated payments firm American Express Co. (AXP) reported Friday that net income for the third quarter declined to $1.1 billion or $1.30 per share from $1.8 billion or $2.08 per share in the prior-year quarter. Consolidated total revenues, net of interest expense, also decreased 20 percent to $8.8... The Federal Trade Commission or FTC has launched a new fraud reporting platform, using which, consumers can easily report fraud and all other consumer issues directly to the regulator. In a statement, the FTC said its new website, ReportFraud.ftc.gov, will provide a streamlined and user-friendly way to submit reports about scams, frauds, and bad business practices.
Follow RTT